CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 28 target
Drug / intervention
metformin/glimepiride combination +2 moredrug
Likely dose
metformin/glimepiride combination 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00941161
NCT00941161Phase 4Completed
CompareCT.gov

Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy

Laboratorios Silanes S.A. de C.V.·interventional·Posted Jul 17, 2009·Updated May 18, 2010

In Brief

A Phase 4 clinical trial evaluating metformin/glimepiride combination, metformin, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The aim of the study is to determinate the effect of combined oral therapy of long acting metformin/glimepiride in a single dose in patients with type 2 diabetes mellitus and monotherapy failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 17, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.0 years ago

Interventions

metformin/glimepiride combinationdrug

long acting metformin/glimepiride 1g/2mg

metformindrug

long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL

glimepiridedrug

glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL